12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ipragliflozin: Phase III data

A double-blind, Japanese Phase III trial in 151 Type II diabetics with inadequate glycemic control on pioglitazone showed that once-daily 50 mg ipragliflozin as an add-on to pioglitazone met the primary endpoint of reducing HbA1c from baseline to week 24 vs. placebo (0.64% vs. a 0.22% increase, p<0.001). Additionally, a greater proportion of patients receiving ipragliflozin achieved a target HbA1c...

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >